# EDGAR Filing Document

**Accession Number:** 0001951205
**File Stem:** 0001209191-23-005349
**Filing Date:** 2023-1
**Character Count:** 8971
**Document Hash:** faeeb9a0d551eeb598fba0d6225033c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-005349.hdr.sgml**: 20230127

**ACCESSION NUMBER**: 0001209191-23-005349

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221114

**FILED AS OF DATE**: 20230127

**DATE AS OF CHANGE**: 20230127

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Neuman Linda L
- **CENTRAL INDEX KEY:** 0001951205

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37722
- **FILM NUMBER:** 23564706

**MAIL ADDRESS:**
- **STREET 1:** C/O AEGLEA BIOTHERAPEUTICS, INC.
- **STREET 2:** 805 LAS CIMAS PARKWAY, SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aeglea BioTherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001636282
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464312787
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 805 LAS CIMAS PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746
- **BUSINESS PHONE:** (512) 942-2935

**MAIL ADDRESS:**
- **STREET 1:** 805 LAS CIMAS PARKWAY
- **STREET 2:** SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78746

## Ex-24

```

                              POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Jonathan Alspaugh and James Kastenmayer, and each of them, as  true and
lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of Aeglea BioTherapeutics, Inc. (the "Company"), any and all
Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be
filed by the undersigned in accordance with Section 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect
to transactions in the Company's securities;

(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID, or Form
3, 4 or 5 report and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or similar
authority; and

(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in his or
her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary, and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or his or her
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted.  The
undersigned acknowledges that no such attorney-in-fact, in serving in such
capacity at the request of the undersigned, is hereby assuming, nor is the
Company hereby assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.

N WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 13th day of October, 2022.

/s/ Linda Neuman
Name:  Linda Neuman

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Neuman Linda L<br><sub>(Last) (First) (Middle)</sub><br>C/O AEGLEA BIOTHERAPEUTICS, INC.<br>805 LAS CIMAS PARKWAY, SUITE 100<br><sub>(Street)</sub><br>AUSTIN, TX 78746<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aeglea BioTherapeutics, Inc. [ AGLE ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-11-14 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 4000 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (right to buy) | <sup>(1)</sup> | 2031-04-22 | Common Stock | 40000 | $7.82 | D |  |
| Employee Stock Option (right to buy) | <sup>(2)</sup> | 2032-02-16 | Common Stock | 30000 | $3.17 | D |  |
| Employee Stock Option (right to buy) | <sup>(3)</sup> | 2032-04-14 | Common Stock | 25000 | $1.90 | D |  |
| Employee Stock Option (right to buy) | <sup>(4)</sup> | 2032-08-22 | Common Stock | 41250 | $0.68 | D |  |

---

### Footnotes:

(1) The options will vest as to 1/4th of the total shares on April 12, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on April 12, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(2) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(3) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on May 15, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(4) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48th of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ James Kastenmayer, by power of attorney  
**Date:** 2023-01-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**